SCHEMBL6525112

SCHEMBL6525112

[CH2]CN1CCN(Cc2cc3ccccc3o2)CC1

nearest known ligand 0.73

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 16/20 0.73
HTR1A P08908 11/20 0.73
DRD2 P14416 9/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2979920 0.85 HTR2B (0.74) HTR2BHTR1ADRD2
SCHEMBL6649681 0.84 HTR2B (0.73) HTR2BHTR1ADRD2
SCHEMBL4754279 0.84 HTR2B (1.00) HTR2BHTR1ADRD2
SCHEMBL2987620 0.84 HTR2B (0.72) HTR2BHTR1ADRD2
SCHEMBL2983918 0.83 HTR2B (0.70) HTR2BHTR1ADRD2
SCHEMBL2734626 0.81 HTR2B (0.68) HTR2BHTR1ADRD2
SCHEMBL13940578 0.81 HTR2B (0.68) HTR2BHTR1ADRD2
SCHEMBL27782046 0.80 HTR2B (0.70) HTR2BHTR1ADRD2
SCHEMBL13499610 0.79 HTR2B (0.65) HTR2BHTR1ADRD2
SCHEMBL22113436 0.76 HTR2B (0.73) HTR2BHTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110052723-A1 USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2011-03-03 US claimed
US-20170112829-A1 USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2017-04-27 US disclosed